6-hydroxybenzothiazole has been researched along with alpha-synuclein in 1 studies
| Studies (6-hydroxybenzothiazole) | Trials (6-hydroxybenzothiazole) | Recent Studies (post-2010) (6-hydroxybenzothiazole) | Studies (alpha-synuclein) | Trials (alpha-synuclein) | Recent Studies (post-2010) (alpha-synuclein) |
|---|---|---|---|---|---|
| 6 | 0 | 2 | 10,821 | 29 | 8,011 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abadi, AH; Abdel-Halim, M; AlNajjar, YT; Becker, W; ElHady, AK; Engel, M; Gabr, M; Salah, M; Wilms, G | 1 |
1 other study(ies) available for 6-hydroxybenzothiazole and alpha-synuclein
| Article | Year |
|---|---|
Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A/α-synuclein aggregation inhibitors with neuroprotective effects.
Topics: alpha-Synuclein; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Dyrk Kinases; HEK293 Cells; Humans; Molecular Structure; Neuroprotective Agents; Protein Aggregates; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Structure-Activity Relationship; Thiazoles; Urea | 2022 |